Latest news for Relief Therapeutics (OTC:RLFTY) Stock

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Biotech

News

Penny Stocks

Health Care

Movers

Trading Ideas

General

NRXP

RLFTF

RLFTY

Relief Therapeutics Holding SA&#39;s (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the 

FDA Denies Breakthrough Tag For NRx Pharma&#39;s COVID-19 Candidate

RELIEF THERAPEUTICS S/ADR by RELIEF THERAPEUTICS HLDG AG

Relief Therapeutics Holding SA

A legal dispute between the companies behind popular television game shows &#8220;Wheel of Fortune&#8221; and &#8220;Jeopardy!&#8221; <a href="https://www.benzinga.com/quote/SONY">has broken out</a>.
What To Know: Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) and CBS, which is owned by Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>), have worked together on the iconic game shows for years. Sony produces &#8220;Wheel of Fortune&#8221; and &#8220;Jeopardy!&#8221; and CBS oversees the distribution.
Sony on Thursday filed a lawsuit against CBS, claiming the company earned distribution fees from unauthorized deals and has become incapable of properly distributing the shows, according to a Wall Street Journal <a href="https://www.wsj.com/business/media/jeopardy-and-wheel-of-fortune-at-center-of-legal-feud-between-sony-and-cbs-d744b6fc">report</a>.
Sony alleged that CBS has assigned improper value to the shows to serve its own interests, including licensing the shows at prices below market rates and favoring its own shows when setting up distribution deals or selling ads. 
CBS has been in charge of distribution for the game shows since 1999, receiving 35% to 40% commissions on the fees television stations pay to carry the shows. The report indicates that typical distribution commissions are usually closer to 15%. &#8220;Wheel of Fortune&#8221; and &#8220;Jeopardy!&#8221; generate more than $100 million in profits each year, according to a person familiar with the matter.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41666494/apple-q4-earnings-revenue-beat-eps-beat-installed-base-hits-new-highs-iphone-sales-rise-as-apple-in">Apple Q4 Earnings: Revenue Beat, EPS Beat, Installed Base Hits New Highs, iPhone Sales Rise As Apple Intelligence &#8216;Supercharges&#8217; Product Lineup</a>
Sony claimed CBS entered into long-term contract agreements with networks in New Zealand and Australia, which breaches contract terms that prohibit the company from signing deals that span more than two years.
Sony also alleged that layoffs at CBS have negatively impacted the teams that work on the iconic shows. 
"CBS has gutted the teams responsible for fulfilling its contractual obligations, requiring us to step in at our own expense," Sony said in a statement.
Sony reportedly said it&#8217;s seeking damages and plans to try to end its agreement with CBS to pursue alternative distribution and advertising partners. 
Shares of CBS parent Paramount Global were down 0.37% in after-hours, trading at $10.90 at the time of publication Thursday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/10/41633013/sony-adds-new-death-note-game-to-november-ps-plus">Sony Adds New Death Note Game To November PS Plus</a></li>
</ul>
Photos: IMDb

Entertainment

Legal

Media

PARA

PARAA

Sony Group Corporation American Depositary Shares

SONY

Sony Sues CBS, Alleges Breach Of Contract Related To Iconic Game Shows 'Wheel Of Fortune,' 'Jeopardy!'

Business Outlook
Intel's guidance for the fourth quarter of 2024 includes both GAAP and non-GAAP estimates as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Q4 2024</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">GAAP</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Non-GAAP</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$13.3-14.3 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">36.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">39.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax Rate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(50)%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">13%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings (Loss) Per Share Attributable to Intel—Diluted</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$(0.24)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.12</td>
</tr>
</tbody>
</table>
</figure>
Reconciliations between GAAP and non-GAAP financial measures are included below. Actual results may differ materially from Intel's business outlook as a result of, among other things, the factors described under "Forward-Looking Statements" below. The gross margin and EPS outlook are based on the mid-point of the revenue range.

Guidance

INTC

Intel Sees Q4 2024 Non-GAAP EPS $0.12 Vs $0.08 Est.; Revenue $13.3B-$14.3B Vs $13.66B Est.

A recent analysis by the Centers for Disease Control and Prevention (CDC) reveals that workers in the food service and hospitality industries are among the highest consumers of <a href="https://www.benzinga.com/markets/cannabis/22/01/25169588/how-cannabis-legalization-is-changing-the-american-workplace">marijuana in the United States. </a>
The study, <a href="https://ajph.aphapublications.org/doi/10.2105/AJPH.2024.307788">published</a> in the American Journal of Public Health, draws from five years of federal health survey data, specifically the CDC's Behavioral Risk Factor Surveillance System (BRFSS) from 2016 to 2020.
<h3 class="wp-block-heading">Key Findings From The Study</h3>
Researchers gathered data from 128,615 individuals across 15 states, including Alaska, Colorado, Florida and Illinois. They discovered significant variations in cannabis use across different industries and occupations.
See Also: <a href="https://www.benzinga.com/markets/cannabis/23/08/33505217/cannabis-use-during-off-hours-not-associated-with-elevated-risk-of-workplace-accidents-finds-new">Cannabis Use During Off-Hours Not Associated With Elevated Risk Of Workplace Accidents, Finds New Study</a>
For instance, about 20.7% of employees in accommodation and food services reported using marijuana and 17.5% in arts, entertainment and recreation field. In contrast, law enforcement showed the lowest prevalence, with only 0.5% of workers reporting recent use.
When examined by occupation, food preparation and serving-related jobs led with 21.9%, followed by roles in arts and media at 17.0%. Interestingly, jobs in education and healthcare showed lower rates, with only 5.7% and 4.7% reporting cannabis use, respectively. Overall, the study found that approximately 10.7% of workers aged 18 and older reported past-month cannabis use.
<h3 class="wp-block-heading">Implications For Workplace Policies</h3>
The researchers noted that the findings can shape future discussions on workplace policies concerning drug use. They pointed out the need for strategies that minimize the risks associated with cannabis consumption, especially in industries prone to high injury rates like construction and forestry. 
"The primary goal for both employers and employees should be to limit the risk of injury while maintaining productivity," the report states.
Despite mixed evidence regarding the relationship between cannabis use and workplace accidents, concerns linger, particularly in safety-sensitive roles. 
"More research is needed to understand factors driving cannabis use in high-risk industries," the authors noted. They also called for clarity on how much cannabis use might affect job performance, stressing that many workers may consume cannabis outside of working hours.
<h3 class="wp-block-heading">Changing Legal Landscape And Workplace Drug Testing</h3>
As cannabis legalization continues to spread across the U.S., employers and policymakers are reevaluating drug testing protocols. Notably, companies like Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and <a href="https://www.benzinga.com/markets/cannabis/24/08/40611728/home-depot-to-end-marijuana-testing-limit-screening-for-most-employees-internal-memo-reveals">Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) have altered their drug screening practices</a>, moving away from pre-employment cannabis testing.
Some states have enacted laws to protect employees from discrimination related to lawful off-duty cannabis use, such as California and <a href="https://www.benzinga.com/markets/cannabis/23/02/31026805/job-seekers-relax-cannabis-use-no-longer-a-barrier-to-employment-in-washington-state">Washington.</a>
In New Jersey, ongoing litigation has emerged over police officers testing positive for THC, revealing conflicts between local governance and state guidelines. Meanwhile, Cleveland Ohio&#8217;s Mayor Justin Bibb announced changes to city job drug testing policies to align with the new cannabis laws.
<h3 class="wp-block-heading">Shifts In Sports And Cannabis Policies</h3>
Professional sports leagues are also revisiting their cannabis policies in response to changing societal views on marijuana. The National Basketball Association (NBA) and Major League Baseball (MLB) have both removed marijuana from their banned substances lists. 
The NCAA followed suit for Division I athletes, and the Ultimate Fighting Championship (UFC) has revised its stance as well.
However, there remains criticism of the World Anti-Doping Agency's ongoing prohibition of cannabis, especially following high-profile cases like that of the world&#8217;s fastest female runner Sha'Carri Richardson who was banned from <a href="https://www.benzinga.com/markets/cannabis/21/07/22025295/the-prohibition-of-cannabis-robbed-shacarri-richardson-but-also-expedited-the-federal-decriminal" target="_blank" rel="noreferrer noopener">competing at the Tokyo Olympics</a> for testing positive for cannabis in 2021.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/02/36896965/wall-street-waves-goodbye-to-weed-testing-how-financial-giants-reshape-job-eligibility-in-the-ca">Wall Street Waves Goodbye To Weed Testing: How Financial Giants Reshape Job Eligibility In The Cannabis Era</a></li>
</ul>
Cover image made with AI.

Cannabis

Gaming

AMZN

Which Industries Have The Highest Cannabis Consumption At Work? New Data Has Answers

Canaccord Genuity analyst Joseph Vafi maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $173 to $300.

Price Target

Analyst Ratings

MSTR

Canaccord Genuity Maintains Buy on MicroStrategy, Raises Price Target to $300

Helport AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPAI#NASDAQ">HPAI</a>) reported quarterly earnings of $47.24 thousand per share. This is a 53.06 percent increase over earnings of $30.86 thousand per share from the same period last year. The company reported $29.58 million in sales this quarter. This is a 132.37 percent increase over sales of $12.73 million the same period last year.

Earnings

HPAI

Helport AI FY EPS $47.24K Up From $30.86 thousand YoY, Sales $29.58M Up From $12.73M YoY

Alliant Energy Provides FY25 EPS Guidance Range Of $3.15 - $3.25 And Annual Common Stock Dividend Target Of $2.03

Nexa Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.12 by 83.33 percent. The company reported quarterly sales of $709.500 million which beat the analyst consensus estimate of $650.039 million by 9.15 percent. This is a 9.32 percent increase over sales of $649.000 million the same period last year.

Earnings Beats

Earnings Misses

NEXA

Nexa Res Q3 2024 Adj. EPS $0.02 Misses $0.12 Estimate, Sales $709.500M Beat $650.039M Estimate

Alliant Energy Narrows 2024 EPS Guidance From $2.99 - $3.13 To $2.99 - $3.06, Est $3.06

Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.10 by 4.55 percent. This is a 9.52 percent increase over earnings of $1.05 per share from the same period last year. The company reported quarterly sales of $1.081 billion which beat $1.076 billion analyst consensus estimate. This is a 0.37 percent increase over sales of $1.08 billion the same period last year.

Alliant Energy Q3 2024 Adj EPS $1.15 Beats $1.10 Estimate, Sales $1.081B Beat $1.076B Estimate

Editors Note: The EPS and estimate were corrected, as was the consensus revenue estimate; bullet points updated.
Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) reported its third-quarter results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/10/b41663729/intel-reports-third-quarter-2024-financial-results">details from the report.&nbsp;&nbsp;</a>
The Details: Intel reported an EPS loss of 46 cents against an estimate of a loss of two cents. Quarterly revenue clocked in at $13.28 billion, which beat the consensus estimate of $13.02 billion.
&#8220;Our Q3 results underscore the solid progress we are making against the plan we outlined last quarter to reduce costs, simplify our portfolio and improve organizational efficiency. We delivered revenue above the midpoint of our guidance, and are acting with urgency to position the business for sustainable value creation moving forward,&#8221; said Pat Gelsinger, Intel CEO. 
&#8220;The momentum we are building across our product portfolio to maximize the value of our x86 franchise, combined with the strong interest Intel 18A is attracting from foundry customers, reflects the impact of our actions and the opportunities ahead,&#8221; Gelsinger added. 
The company recorded an impact of negative 63 cents to non-GAAP EPS attributable to Intel from $3.1 billion of impairment charges.
&#8220;Restructuring charges meaningfully impacted Q3 profitability as we took important steps toward our cost reduction goal,&#8221; said David Zinsner, Intel CFO. &#8220;The actions we took this quarter position us for improved profitability and enhanced liquidity as we continue to execute our strategy. We are encouraged by improved underlying trends, reflected in our Q4 guidance.&#8221;
Outlook: Intel expects fourth-quarter earnings of 12 cents per share and gross margin of 39.5%. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Intel Q3 2024 Earnings Call &#x7C; $INTC" width="500" height="281" src="https://www.youtube.com/embed/sP5p7kadP6U?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">Reddit &#8216;Remains A Favorite&#8217; For Wall Street After &#8216;Emphatic Beat And Raise&#8217; In Q3</a>
INTC Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Intel shares are up 12.27% after-hours at $24.17 at the time of publication Thursday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41497160/starbucks-analysts-bullish-on-ceo-brian-niccol-after-tough-preannouncement-zeroing-">Starbucks Analysts Bullish On CEO Brian Niccol After Tough Preannouncement: &#8216;Zeroing In&#8217; On Right Issues</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Tech

Intel Stock Climbs On Better-Than-Expected Q3 Results: Details (CORRECTED)

Jefferies analyst Omar Nokta maintains Dorian LPG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPG#NYSE">LPG</a>) with a Buy and maintains $42 price target.

Jefferies Maintains Buy on Dorian LPG, Maintains $42 Price Target

CORRECTION: Intel Q3 Adj EPS $(0.46) Misses $(0.02) Estimate, Sales $13.28B Beat $13.02B Estimate

Barrington Research analyst James Goss maintains Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) with a Outperform and maintains $20 price target.

Barrington Research Maintains Outperform on Marcus, Maintains $20 Price Target

Barrington Research analyst James Goss maintains Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) with a Outperform and maintains $2.5 price target.

Barrington Research Maintains Outperform on Clear Channel Outdoor, Maintains $2.5 Price Target

Barrington Research analyst James Goss upgrades Cinemark Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) from Market Perform to Outperform and announces $36 price target.

Upgrades

Barrington Research Upgrades Cinemark Hldgs to Outperform, Announces $36 Price Target

Offerings

Martin Marietta Reports Pricing Of Its Offering Of $750M Of 5.150% Senior Notes Due 2034 And $750M Of 5.500% Senior Notes Due 2054

Barrington Research analyst Alexander Paris maintains Carriage Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSV#NYSE">CSV</a>) with a Outperform and raises the price target from $39 to $45.

Barrington Research Maintains Outperform on Carriage Servs, Raises Price Target to $45

The second of three monthly contests in Benzinga&#8217;s paper trading competition powered by TradeZero kicked off on Oct. 15, giving contestants a chance to take home a portion in the more than $30,000 in cash and prizes offered during&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">the three-month run.</a>
While contestants are already battling for the top position on the leaderboard and a $10,000 cash prize, it&#8217;s not too late to sign up for the contest that runs through Nov. 14.
The Contests:&nbsp;Powered by&nbsp;TradeZero, the&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">World Championship of Trading</a>&nbsp;is the ultimate trading competition for investors to prove their keen eye during a three-month time period.
The first of three separate contests kicked off on Monday, Sept. 16. Over $5,000 in cash will be awarded to verified contest winners from the first contest.
With the first contest over, everyone who signs up for the second portion will now compete for the top prize of $10,000 in cash, a lifetime of&nbsp;Benzinga Pro Essential&nbsp;and a tour of the&nbsp;New York Stock Exchange&nbsp;with lunch for two at the exchange.
Contestants have until Nov. 7 to sign up for the second contest, with everyone starting over with a paper balance of $100,000. Based on the last contest's results, investors may want to sign up and start trading today.
Each investor will have around one month across three separate contests to generate the highest profits from a starting balance of $100,000 in a simulated trading account.
Contestants in the World Championship of Trading will have access to Benzinga&#8217;s Live Squawk product.
Investors will also gain exposure to TradeZero&#8217;s newly patented short-selling tools.
Through Oct. 27, this is the current leaderboard for the second contest:
1st: XiaoTian Z.: $635,435
2nd: Sebastian N.: $349,712
3rd: Edward N.: $325,834
Each of the top 10 contestants on the leaderboard has a balance of at least $213,000, which means anyone joining the contest needs to sign up today and start trading to catch up.
Only Edward N. ranked among the top 10 on last week's leaderboard, which shows that traders who join the contest late or try to have consistent gains can climb up the rankings. From last week's top 10, former first place holder Mark D. is no longer in the top 10, former second place Joseph C. fell to seventh and former third place Shruthi M. fell to fourth.
The good news for late joiners is the leaderboard changed rather consistently week to week during the first contest.
First Contest Winner: Andrea S., the winner of the first contest, went from $100,000 to more than $1 million in the paper trading account in <a href="https://www.benzinga.com/exclusives/24/10/41240862/benzinga-world-championship-of-trading-powered-by-tradezero-1-contestant-up-988-in-3-weeks-join-now" target="_blank" rel="noreferrer noopener">less than a month.</a>
Benzinga previously&nbsp;<a href="https://www.youtube.com/live/DjRmtokM2YQ?si=V0zxoFo4dHh0jPGT&amp;start=3615" target="_blank" rel="noreferrer noopener">interviewed&nbsp;</a>Andrea S., who was in the top 10 for most of the contest and was in first place several weeks. Official results coming soon will show whether Andrea held onto the lead to take home the top prize in the first contest.
Contest Rules:&nbsp;The contest is open to residents of the United States and Canada who are 21 years of age or older.
Traders will be able to buy simulated equities and options from U.S. markets during the contest periods starting with a balance of $100,000. No fractional shares will be allowed. Traders have to hold a minimum of one stock or option throughout the contest. A minimum of five days of one trade or more must be completed throughout each contest.
Interested investors have been able to&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">sign up to join</a>&nbsp;the contest since Friday, July 26. Signing up for the first contest will automatically register an entry in the second and third contests. Traders can sign up for the contests after the start dates as long as it is before a cutoff deadline.
The dates for the&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">contests</a>&nbsp;are listed below:
<ul>
<li>Contest 1: Sept. 15 through Oct. 14</li>
<li>Contest 2: Oct. 15 through Nov. 14</li>
<li>Contest 3: Nov. 15 through Dec. 14</li>
</ul>
The last days to register for the remaining contests are at 9 a.m. ET on Nov. 7 and Dec. 8.
Read Also:&nbsp;<a href="https://www.benzinga.com/fintech/23/11/35687369/tradezero-ceo-daniel-pipitone-giving-the-retail-traders-an-institutional-level-toolbox" target="_blank" rel="noreferrer noopener">TradeZero CEO Daniel Pipitone: Giving Retail Traders An Institutional-Level Toolbox</a>
Contest Prizes: Participants have the chance to win as much as $30,000 in cash and prizes during the contests. Travel and expenses will not be paid for the NYSE tour prizes.
Here are the prizes for the World Championship of Trading.
Contest 1:
<ul>
<li>First Place: $5,000 cash, lifetime of&nbsp;<a href="https://pro.benzinga.com/feature/newsfeed/?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348" target="_blank" rel="noreferrer noopener">Benzinga Pro Essential,</a>&nbsp;tour of the NYSE and lunch for two at the NYSE.</li>
<li>Second Place: $1,000 cash, one year of Benzinga Pro Essential.</li>
<li>Third Place: $500 cash, one year of Benzinga Pro Essential.</li>
</ul>
Contest 2:
<ul>
<li>First Place: $10,000 cash, lifetime of Benzinga Pro Essential, tour of the NYSE and lunch for two at the NYSE.</li>
<li>Second Place: $2,000 cash, one year of Benzinga Pro Essential.</li>
<li>Third Place: $1,000 cash, one year of Benzinga Pro Essential.</li>
</ul>
Contest 3:
<ul>
<li>First Place: $15,000 cash, lifetime of Benzinga Pro Essential, tour of the NYSE and lunch for two at the NYSE.</li>
</ul>
Find out more at the&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">World Championship of Trading site</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a></li>
</ul>
The World Championship of Trading (the &#8220;Contest&#8221;) involves the assembling and managing of a fantasy stock portfolio and not actual trading results. Contest information and results (collectively, the "Content") have been made available for information and entertainment purposes only and should not be considered trading or investment advice or a recommendation as to any security. All trading involves risks. Neither Benzinga nor TradeZero make any representations and warranties with respect to the accuracy of the Content, nor do they accept any liability which may arise directly or indirectly from use of the Content. See the&nbsp;<a href="https://tradezeroedge.com/world-championship-of-trading/contest-instructions" target="_blank" rel="noreferrer noopener">Contest&#8217;s official rules</a>&nbsp;for all terms and conditions. TradeZero provides self-directed brokerage accounts to customers through its operating affiliates: TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas; and TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of the Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF). If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero broker dealer in your jurisdiction.

Exclusives

Benzinga World Championship Of Trading Powered By TradeZero Top Trader Is Up Over 600%: Think You Can Pass Them In 2 Weeks? There's Still Time To Compete For Cash Prizes

Needham analyst Quinn Bolton maintains Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Buy and lowers the price target from $33 to $30.

ALGM

Needham Maintains Buy on Allegro Microsystems, Lowers Price Target to $30

DA Davidson analyst Linda Bolton Weiser maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Neutral and lowers the price target from $13 to $7.5.

DA Davidson Maintains Neutral on Herbalife, Lowers Price Target to $7.5

Relief Therapeutics grants exclusive U.S. rights to Eton Pharmaceuticals for PKU GOLIKE

Relief Therapeutics forms new executive leadership team, names new CFO

Relief Therapeutics reports 1H results

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Relief gains as experimental therapy performs on par with BioMarin's Kuvan

ATYR

BMRN

ETON

NVSEF

ROIV

Press Releases

Relief Therapeutics Secures up to $11 Million from Royalty Sales

Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement

Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

Relief Therapeutics

Relief Therapeutics Holding SA&#39;s&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RLFTF#OTC">RLFTF</a>) collaborating partner&nbsp;NRx Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) has announced that the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/11/ac24268379/relief-reports-that-its-u-s-collaboration-partner-has-announced-the-u-s-food-and-drug-administrat" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA has denied Breakthrough Therapy Designation</a>&nbsp;for aviptadil.&nbsp;

<ul>
	<li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>
	<li>Related content:&nbsp;Benzinga&#39;s Full&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/calendars/fda#historical" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA Calendar</a>.</li>
	<li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.&nbsp;</li>
	<li>Therefore, the denial does not impede NRx&#39;s ability to seek drug approval.</li>
	<li>Relief&#39;s lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>
	<li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.&nbsp;</li>
	<li>Related Link:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/11/24043451/nrx-pharmas-covid-19-candidate-receives-fda-review-for-manufacturing-information" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">NRx Pharma&#39;s COVID-19 Candidate Receives FDA Review For Manufacturing Information</a>.</li>
	<li>Price Action:&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>
</ul>

Comments

Relief Therapeutics

News

Latest news for Relief Therapeutics (OTC:RLFTY) Stock

Wednesday, November 24, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga